Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : MiNK Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
MiNK And Autonomous Collaborate on Novel Therapies For Metastatic Tumors
Details : The collaboration will leverage Autonomous’ precision encRNA technology and MiNK’s innovative iNKT cell therapies, MiNK-215, an investigational, off-the-shelf cellular immunotherapy, and agenT-797.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 10, 2024
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : MiNK Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration